3/19
06:32 am
xene
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Neutral
Report
Xenon Pharmaceuticals (NASDAQ:XENE) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
3/12
04:01 pm
xene
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
Low
Report
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
3/9
12:17 am
xene
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ... [Yahoo! Finance]
Medium
Report
Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ... [Yahoo! Finance]
3/5
04:01 pm
xene
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
Low
Report
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
3/2
08:46 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
11:15 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Royal Bank of Canada from $56.00 to $55.00. They now have an "outperform" rating on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target lowered by analysts at Royal Bank of Canada from $56.00 to $55.00. They now have an "outperform" rating on the stock.
3/1
09:03 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target raised by analysts at Wedbush from $46.00 to $51.00. They now have an "outperform" rating on the stock.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target raised by analysts at Wedbush from $46.00 to $51.00. They now have an "outperform" rating on the stock.
2/29
04:51 pm
xene
Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results [Yahoo! Finance]
2/29
04:13 pm
xene
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
2/29
04:06 pm
xene
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Financial Post (Toronto, Ontario, Canada)]
2/29
04:01 pm
xene
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Low
Report
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2/22
04:01 pm
xene
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
Low
Report
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
2/8
05:01 pm
xene
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks' [Seeking Alpha]
Medium
Report
Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks' [Seeking Alpha]
2/8
01:12 pm
xene
Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive Therapeutics, Takeda, Ovid Therapeutics, Eisai, Biohaven Pharmaceuticals, UCB Pharma [Yahoo! Finance]
Low
Report
Epilepsy Market to Observe Stunning Growth by 2032, Predicts DelveInsight | Key Players in the Market - Xenon Pharmaceuticals, Aquestive Therapeutics, Takeda, Ovid Therapeutics, Eisai, Biohaven Pharmaceuticals, UCB Pharma [Yahoo! Finance]
1/25
09:51 am
xene
Epilepsy Market Insight, Epidemiology and Market Forecast to 2032 [Yahoo! Finance]
Low
Report
Epilepsy Market Insight, Epidemiology and Market Forecast to 2032 [Yahoo! Finance]
1/23
10:40 am
xene
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now [Yahoo! Finance]
Low
Report
Here's Why You Should Add Xenon (XENE) to Your Portfolio Now [Yahoo! Finance]
1/8
08:08 am
xene
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 [Yahoo! Finance]
Medium
Report
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 [Yahoo! Finance]
1/8
08:05 am
xene
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 [Financial Post (Toronto, Ontario, Canada)]
1/8
08:00 am
xene
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
Medium
Report
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
1/4
08:07 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $62.00 price target on the stock.
Medium
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $62.00 price target on the stock.
1/3
08:41 am
xene
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/3
08:32 am
xene
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference [Financial Post (Toronto, Ontario, Canada)]
1/3
08:30 am
xene
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Low
Report
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2
10:55 am
xene
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target raised by analysts at Bank of America Co. from $52.00 to $56.00. They now have a "buy" rating on the stock.
Low
Report
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) had its price target raised by analysts at Bank of America Co. from $52.00 to $56.00. They now have a "buy" rating on the stock.